TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06753305

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gingivectomy and gingivoplasty surgery and periodontal paste +ozone therapy application
Description: After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Periodontal paste (Coe-pak) will be applied to the area left for secondary healing after ozone therapy (activated oxygen (Cure 09 Active Oxygen))

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gingivectomy and gingivoplasty surgery and periodontal paste application
Description: After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Only periodontal paste will be applied after the surgery.
Study: NCT06752369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1D-specific depression SSI
Description: The T1D-specific depression SSI will include 1) psychoeducation about depression, including how behavior shapes feelings and thoughts, 2) a values assessment, where youth will identify key areas (i.e., family relationships, friendships, school, or hobbies) from which they draw (or once drew) enjoyment and meaning, and 3) the creation of an activity action plan, wherein youth identify (from pre-generated lists) and personalize (in guided exercises) three activities to target for change.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: T1D Educational
Description: T1D Educational Material
Study: NCT06753994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitor
Description: Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia. In this study, participants will start with a dose of 2.5 mg of empagliflozin for four weeks, which will then be increased to 10 mg for the following nine weeks.
Study: NCT06753669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education and social network building
Description: The investigators will use techniques from the social network literature to build each treatment group as a cohesive social network and will diffuse educational messages through these groups.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: dental referral and educational materials
Description: Control arm will receive a referral to vetted dentist and educational materials on child health
Study: NCT06754852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB-002 (Part A)
Description: HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB-002 (Part B)
Description: HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.
Study: NCT06755060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-assisted medical decision support system
Description: The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. Patients in the intervention group will undergo standard ophthalmic examinations, with clinical decisions guided by the recommendations generated by the AI system. In contrast, patients in the control group will receive only standard ophthalmic examinations and treatment, without the support of AI-assisted decision-making tools.
Study: NCT06754462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: Administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: Administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IMVT-1402
Description: Administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once weekly by subcutaneous injection.
Study: NCT06754163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)
Description: Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.~To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly. The semaglutide injection will be administered once weekly on the same day of the week throughout the study period. Injections will be administered in the thigh, abdomen or upper arm at any time of the day. As part of the multi-disciplinary approach taken in the STEP trials of Wegovy, patients willl be encouraged to~* Increase their physical activity~* Reduce their daily calorie intake~* Record their physical activity and dietary intake on their Food/Activity/Sleep (FAS) Diary Sheets A secondary goal is to achieve sustained improvements in participants' activity levels and awareness of a healthy diet.
Study: NCT06753422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kefir
Description: 200 ml/day kefir~The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota.
Study: NCT06751979

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: Daily intake of a lozenge containing the probiotic strain S. salivarius M18.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06751667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary biomarkers
Description: In a bid to reduce or replace surveillance cystoscopies multiple urinary biomarkers have been evaluated for the follow-up of the bladder cancer patients. These device will reduce the number of cystoscopies
Study: NCT06753175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: underwater galvanic stimulation by 4-cell bath
Description: Underwater Galvanic Stimulation:~* Equipment: 4-cell bath~* Procedure: Patients will immerse their affected limbs in the 4-cell bath. Electrical stimulation will be applied at a frequency of 15 Hz and intensity of 20 mA for 20 minutes, 3 times per week (Han et al. 2020).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy (CDT):
Description: Complete Decongestive Therapy (CDT):~* Manual Lymphatic Drainage (MLD): 60 minutes per session, 3 days per week.~* Compression Therapy: Multilayer bandaging applied after MLD.~* Exercise: Specific exercises performed with compression in place.~* Skin Care: Routine skin and nail care to prevent infections (Curlett et al. 2020).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy (CDT):
Description: Complete Decongestive Therapy (CDT):~* Manual Lymphatic Drainage (MLD): 60 minutes per session, 3 days per week.~* Compression Therapy: Multilayer bandaging applied after MLD.~* Exercise: Specific exercises performed with compression in place.~* Skin Care: Routine skin and nail care to prevent infections (Curlett et al. 2020).
Study: NCT05073510

Intervention type: DEVICE
Intervention: BVE
Description: Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
Study: NCT06136650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opevesostat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Administered orally or IM as a rescue drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone acetate
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Administered orally
Study: NCT05194072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-B7H4V
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-B7H4V
Description: Given into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg every 6 weeks, given by IV
Study: NCT05321498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: XPro1595 will be delivered by subcutaneous injection once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be delivered by subcutaneous injection once a week
Study: NCT06302101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: chair-based exercises
Description: Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chair-based exercises
Description: Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive exercises
Description: Cognitive exercises will be performed under the supervision of a physiotherapist 1 day a week for 8 weeks as online telerehabilitation for intervention group.
Study: NCT04881045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07257876
Description: CD47-PDL-1 bispecific antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07257876
Description: CD47-PDL-1 bispecific antibody
Study: NCT05958719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide 30mg biw, p.o, 21 days for a cycle.
Study: NCT05920967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Palmitate
Description: a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
Study: NCT05160623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 1 % Topical Solution
Description: Povidone-Iodine 1 % topical solution on a makeup remover pad, used to clean the lids and lashes once daily
Study: NCT05958719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide 30mg biw, p.o, 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal mitoxantrone
Description: 12mg/m2， d1,21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal mitoxantrone
Description: 12mg/m2， d1,21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/m2，d1-5,21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/m2，d1-5,21 days for a cycle.
Study: NCT06269770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol
Description: Add tapentadol, for effective pain management in a multimodal setting during TKR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Add tramadol, for effective pain management in a multimodal setting during TKR.
Study: NCT04712942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
Study: NCT05349617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvant
Description: PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is comprised of formulation buffer
Study: NCT05881759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Revised ESBA
Description: Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of \~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
Study: NCT04497168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Description: 20mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pills
Study: NCT05981768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT04897074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task.
Study: NCT05355168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
Description: neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
Study: NCT06114992

Intervention type: DEVICE
Intervention: Servo-n HFOV modes
Description: Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
Study: NCT05920551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastrocnemius Stretching Exercises
Description: The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
Study: NCT05678400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypopressive abdominal techniques
Description: Both training protocols were carried out in a single intervention for each of the participants assigned to either the HAT or the PNF stretching group. The intervention began with the measurement of hip flexion using the EPR test, and ended with a post-intervention measurement of hip flexion to observe the effects of the treatment. All measurements, as well as the interventions for each of the patients in the two groups, were carried out by the same registered physiotherapist. In order to standardise an order of examination of the lower limbs in the EPR test, the right lower limb was assessed first, followed by the left lower limb. Likewise, the same order was standardised for stretching in the PNF group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching of proprioceptive neuromuscular facilitation
Description: Stretching of proprioceptive neuromuscular facilitation
Study: NCT05160623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid cleansing wipes
Description: EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
Study: NCT06524869

Intervention type: DIAGNOSTIC_TEST
Intervention: Isokinetic neuromuscular assessment
Description: All sports patients who had a muscle evaluation in addition to functional testing at 6-12 months after ACLR since March 2024
Study: NCT05316961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PEMF
Description: PEMF 1.5mT, 10Hz, 10 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF
Description: PEMF 0mT, 0Hz, 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Eccentric exercise, 10 repetitions, 3 sets

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Eccentric exercise
Description: Eccentric exercise, 10 repetitions, 3 sets